Related Experiment Video
Updated: Aug 16, 2026
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
[In vitro antitumor immune response induced by fusion of dendritic cells and Ewing's sarcoma cells]
1Department of Orthopaedic Oncology, Peking University People's Hospital, Beijing 100044, China. tangshun78@sohu.com
Objective:
Human Ewing sarcoma A673 cells and human peripheral blood-derived DCs were fused to induce an antitumor activity against human EW.
Methods:
EW A673 cells and human peripheral blood-derived DCs were fused with polyethylene glycol (PEG).
Results:
Mature DCs with highly expressed surface markers (CD80, CD86, CD83 and HLA-DR) were generated in vitro and flow cytometry. It showed that the highest fusion efficiency was 23.01%. T cell proliferation assay indicated that the novel dendritomas in fused DCs/A673 cells were the most potent in activation of autologous T cell proliferation. The IFN-gamma assay showed that The IFN-gamma secretion by CTLs activated by the novel dendritomas increased more than by other stimulators. CTL assay demonstrated that the novel dendritomas induced A673 cell-specific cytotoxic responses to lyse the A673 cells in the context of MHC class I.
Conclusion:
The data indicates that fusion of tumor cells with DCs is an attractive strategy to induce tumor rejection.
